HENDERSON, NV / ACCESSWIRE / August 30, 2018 / An incredibly interesting biotechnology company that we have discovered is ENDV (Endonovo Therapeutics, Inc.). ENDV is starting to receive significantly increased attention from the street, and if this is your first-time hearing about ENDV start doing your own research immediately.
ENDV has an FDA-Cleared Electroceutical? System, SofPulse®, for the palliative treatment of post-operative pain and edema in superficial soft tissues. Additionally, ENDV recently signed a national distribution agreement for sales, marketing and distribution of SofPulse® targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.which is a very positive development. Start doing your own research on ENDV right away, this company just reported news of a national distribution agreement for their FDA-Cleared medical device. And an 8-K that was released shows ENDV projects $5.25M over the next 15 months in revenues for that device.
These cannabis and biotech companies are on the rise and should be on everyone’s watchlist: Endonovo Therapeutics, Inc. (ENDV), CV Sciences, Inc. (OTCQB:CVSI), and Geron Corporation (GERN).
Endonovo Therapeutics, Inc. (ENDV)
Market Cap: $14.645M, current share price: $0.04
Endonovo Therapeutics (ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical? Therapy. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals? Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company’s non-invasive Electroceutical? System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals? addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals? work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.
CV Sciences, Inc. (OTCQB:CVSI)
Market Cap: $291M Share Price: $3.21
CV Sciences (CVSI) is currently being sought after in a class action lawsuits from several different law firms. These law firms are encourage investors that lost capital due to huge drops in the company’s share price over the last couple of weeks, to contact them for representation. This is never a good thing, but the company’s stock is down considerably, and this could be a good time to buy at the current reduced level.
Geron Corporation (GERN)
Market Cap: $1.001B, current share price: $5.53
Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and sixty eight thousand dollars total by Regal Consulting. LLC, for news commentary articles for ENDV. ENDV and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communication LLC